Case Report: Two Cases of Soft-Tissue Sarcomas: High TMB as a Potential Predictive Biomarker for Anlotinib Combined With Toripalimab Therapy

Case Report: Two Cases of Soft-Tissue Sarcomas: High TMB as a Potential Predictive Biomarker for Anlotinib Combined With Toripalimab Therapy

Soft-tissue sarcomas (STS), with over 100 different histologic subtypes, are rare tumors that account for 1% of all adult malignancies. Immune checkpoint inhibitors (ICIs) display certain benefits in some subtypes, especially in undifferentiated pleomorphic sarcoma (UPS), alveolar soft part sarcoma...

Full description

Bibliographic Details
Main Authors:	Yong Li, Yihong Liu, Yanchun Qu, Xian Chen, Xin Qu, Yongsong Ye, Xiaohua Du, Ying Cheng, Mian Xu, Haibo Zhang
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2022-05-01
Series:	Frontiers in Immunology
Subjects:	soft-tissue sarcomas tumor mutational burden (TMB) immune checkpoint inhibitors anlotinib toripalimab
Online Access:	https://www.frontiersin.org/articles/10.3389/fimmu.2022.832593/full

Similar Items

Case Report: Toripalimab Combined With Anlotinib in a Patient With Metastatic Upper Tract Urothelial Carcinoma After Pembrolizumab Failure
by: Ning Zan, et al.
Published: (2022-02-01)

Toripalimab in combination with Anlotinib for unresectable hepatocellular carcinoma after SBRT: A prospective, single-arm, single-center clinical study
by: Yongbiao Chen, et al.
Published: (2023-03-01)

Effectiveness and Safety of Toripalimab Combination Therapies for Patients With Chemo-Resistant Choriocarcinoma
by: Xiaomei Liu, et al.
Published: (2022-04-01)

TMB in NSCLC: A Broken Dream?
by: Sara Bravaccini, et al.
Published: (2021-06-01)

Efficacy and Safety of Anlotinib Combined with Liposomal Doxorubicin Followed by Anlotinib Maintenance in Metastatic Soft Tissue Sarcomas
by: Liu Z, et al.
Published: (2021-02-01)

Anlotinib: A Novel Targeted Drug for Bone and Soft Tissue Sarcoma
by: Shenglong Li, et al.
Published: (2021-05-01)

Challenges and Future Directions in the Management of Tumor Mutational Burden-High (TMB-H) Advanced Solid Malignancies
by: Jibran Ahmed, et al.
Published: (2023-12-01)

Pembrolizumab combined with anlotinib improves therapeutic efficacy in pulmonary sarcomatoid carcinoma with TMB-H and PD-L1 expression: a case report and literature review
by: Shugui Wu, et al.
Published: (2023-10-01)

Efficacy and safety of anlotinib in patients with unresectable or metastatic bone sarcoma: A retrospective multiple institution study
by: Zhiyong Liu, et al.
Published: (2021-11-01)

Stuttering as a signal of encephalopathy associated with toripalimab in a pancreatic ductal adenocarcinoma patient: a case report
by: Jianping He, et al.
Published: (2023-03-01)

Gemcitabine Plus Anlotinib Is Effective and Safe Compared to Gemcitabine Plus Docetaxel in Advanced Soft Tissue Sarcoma
by: Zhiyong Liu, et al.
Published: (2022-07-01)

Open the Technical Black Box of Tumor Mutational Burden (TMB): Factors Affecting Harmonization and Standardization of Panel-Based TMB
by: Meng-Ta Sung, et al.
Published: (2022-05-01)

Effectiveness and Tolerability of Anlotinib Plus PD-1 Inhibitors for Patients with Previously Treated Metastatic Soft-Tissue Sarcoma
by: Sun X, et al.
Published: (2022-09-01)

Case Report: An Adolescent Soft Tissue Sarcoma With YWHAE-NUTM2B Fusion Is Effectively Treated With Combined Therapy of Epirubicin and Anlotinib
by: Jiajia He, et al.
Published: (2022-06-01)

Epithelioid hemangioendothelioma of the retroperitoneal giant type treated with Toripalimab: A case report
by: Yuqing Bu, et al.
Published: (2023-03-01)

Anti-GAD65 Antibody-Associated Autoimmune Encephalitis With Predominant Cerebellar Involvement Following Toripalimab Treatment: A Case Report of a Novel irAE of Toripalimab
by: Huanyu Zhou, et al.
Published: (2022-03-01)

Case Report: Successful Treatment of Kaposi’s Sarcoma With Anlotinib in an HIV-Negative Patient After the Treatment of Drug Reaction With Eosinophilia and Systemic Symptoms Accessory Tragus
by: Min Lin, et al.
Published: (2022-05-01)

Phase 2 trial of neoadjuvant toripalimab with chemotherapy for resectable stage III non-small-cell lung cancer
by: Ze-Rui Zhao, et al.
Published: (2021-01-01)

An exploration of LAF‐bTMB as a predictor for the efficacy of immunotherapy combined with chemotherapy in non—small cell lung cancer
by: Shuyang Zhang, et al.
Published: (2022-12-01)

Toripalimab combined with concurrent platinum-based Chemoradiotherapy in patients with locally advanced cervical Cancer: an open-label, single-arm, phase II trial
by: Jie Chen, et al.
Published: (2022-07-01)

FAM83D acts as an oncogene by regulating cell cycle progression via multiple pathways in synovial sarcoma: a potential novel downstream target oncogene of anlotinib
by: Zi-mei Liu, et al.
Published: (2024-03-01)

Efficacy and safety of anlotinib, a multikinase angiogenesis inhibitor, in combination with epirubicin in preclinical models of soft tissue sarcoma
by: Zhi‐Ming Wang, et al.
Published: (2020-05-01)

The prognostic value of tumor mutation burden (TMB) and its relationship with immune infiltration in breast cancer patients
by: Shengjin Cui, et al.
Published: (2023-02-01)

Anlotinib as a maintenance treatment for advanced soft tissue sarcoma after first-line chemotherapy (ALTER-S006): a multicentre, open-label, single-arm, phase 2 trialResearch in context
by: Bushu Xu, et al.
Published: (2023-10-01)

Toripalimab plus chemotherapy vs. chemotherapy in patients with advanced non-small-cell lung cancer: A cost-effectiveness analysis
by: Gengwei Huo, et al.
Published: (2023-02-01)

Relationship between tumor mutational burden, gene mutation status, and clinical characteristics in 340 cases of lung adenocarcinoma
by: Kai Ma, et al.
Published: (2022-11-01)

Efficacy and Safety of PD-1 Inhibitor Combined with Anlotinib on Advanced Neuroendocrine Carcinoma
by: YU Xuxu, et al.
Published: (2021-10-01)

Flat dose regimen of toripalimab based on model-informed drug development approach
by: Lili Li, et al.
Published: (2023-01-01)

Case Report: Toripalimab: a novel immune checkpoint inhibitor in advanced nasopharyngeal carcinoma and severe immune-related colitis
by: Canhua Luo, et al.
Published: (2023-11-01)

Application of Anlotinib Combined With Neoadjuvant Chemotherapy in Primary EWS/PNET of Lung: A Case Report
by: YH Fan, et al.
Published: (2022-04-01)

The Prognostic Value of ctDNA and bTMB on Immune Checkpoint Inhibitors in Human Cancer
by: Jiayan Wei, et al.
Published: (2021-10-01)

Radiofrequency ablation combined with toripalimab for recurrent hepatocellular carcinoma: A prospective controlled trial
by: Zhenyu Wen, et al.
Published: (2023-10-01)

Biological Pathway-Derived TMB Robustly Predicts the Outcome of Immune Checkpoint Blockade Therapy
by: Ya-Ru Miao, et al.
Published: (2022-09-01)

The Sequence of Chemotherapy and Toripalimab Might Influence the Efficacy of Neoadjuvant Chemoimmunotherapy in Locally Advanced Esophageal Squamous Cell Cancer—A Phase II Study
by: Wenqun Xing, et al.
Published: (2021-12-01)

Case report: Immunotherapy in rare high TMB pancreatic acinar carcinoma
by: Guifu Wu, et al.
Published: (2024-03-01)

Toripalimab: the First Domestic Anti-Tumor PD-1 Antibody in China
by: Lin Zhang, et al.
Published: (2022-01-01)

Anlotinib Exerts Inhibitory Effects against Cisplatin-Resistant Ovarian Cancer In Vitro and In Vivo
by: Yurou Ji, et al.
Published: (2022-12-01)

Cost-effectiveness analysis of toripalimab for metastatic or recurrent triple-negative breast cancer
by: Jiangbo Shao, et al.
Published: (2024-01-01)

Case report: Unique FLT4 variants associated with differential response to anlotinib in angiosarcoma
by: Yuanyuan Gu, et al.
Published: (2022-11-01)

A phase I study of toripalimab, an anti‐PD‐1 antibody, in patients with refractory malignant solid tumors
by: Xiao‐Li Wei, et al.
Published: (2020-08-01)